Bull
$3.63
シナリオ価格
$3.410
-0.459 (-13.45%)終値時点
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
IM Cannabis Corp is not a good buy right now due to its current price of $3.41, a year-to-date change of -92.37%, and ongoing financial losses. The company's gross margin has dropped to 19.83% in Q2 2026, indicating declining profitability. Additionally, the stock is under pressure from Nasdaq compliance issues, which could further impact its liquidity and market perception.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

IM Cannabis Announces 30-for-1 Share Consolidation to Meet Nasdaq Compliance

IM Cannabis Announces Share Consolidation Plan

IM Cannabis Corp. Approves Share Consolidation to Regain Nasdaq Compliance

IM Cannabis Corp. Finalizes Share Purchase Agreement to Enhance Equity

IM Cannabis Reports Financial Results for Q2 2026
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
IM Cannabis Corp is not a good buy right now due to its current price of $3.41, a year-to-date change of -92.37%, and ongoing financial losses. The company's gross margin has dropped to 19.83% in Q2 2026, indicating declining profitability. Additionally, the stock is under pressure from Nasdaq compliance issues, which could further impact its liquidity and market perception.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。